Does the media prefer VRDN or PACS?

In the previous week, Viridian Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 10 mentions for Viridian Therapeutics and 8 mentions for PACS Group. Viridian Therapeutics' average media sentiment score of 1.22 beat PACS Group's score of 1.16 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or HIMS?

In the previous week, Hims & Hers Health had 15 more articles in the media than Viridian Therapeutics. MarketBeat recorded 25 mentions for Hims & Hers Health and 10 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Hims & Hers Health's score of 0.22 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 5 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor VRDN or BLLN?

In the previous week, Viridian Therapeutics had 5 more articles in the media than Billiontoone. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for Billiontoone. Viridian Therapeutics' average media sentiment score of 1.22 beat Billiontoone's score of 0.41 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SHC or VRDN?

In the previous week, Sotera Health and Sotera Health both had 10 articles in the media. Sotera Health's average media sentiment score of 1.35 beat Viridian Therapeutics' score of 1.22 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RDNT or VRDN?

In the previous week, Viridian Therapeutics had 5 more articles in the media than RadNet. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for RadNet. Viridian Therapeutics' average media sentiment score of 1.22 beat RadNet's score of 0.42 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$18.72 -0.20 (-1.06%)

As of 10:50 AM Eastern

Compare

VRDN vs. PACS, HIMS, BLLN, SHC, and RDNT

Should you buy Viridian Therapeutics stock or one of its competitors? MarketBeat compares Viridian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viridian Therapeutics include PACS Group (PACS), Hims & Hers Health (HIMS), Billiontoone (BLLN), Sotera Health (SHC), and RadNet (RDNT).

How does Viridian Therapeutics compare to PACS Group?

Viridian Therapeutics (NASDAQ:VRDN) and PACS Group (NYSE:PACS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Viridian Therapeutics currently has a consensus price target of $38.79, suggesting a potential upside of 107.19%. PACS Group has a consensus price target of $50.60, suggesting a potential upside of 10.43%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Viridian Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Viridian Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, PACS Group has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market.

In the previous week, Viridian Therapeutics had 2 more articles in the media than PACS Group. MarketBeat recorded 10 mentions for Viridian Therapeutics and 8 mentions for PACS Group. Viridian Therapeutics' average media sentiment score of 1.22 beat PACS Group's score of 1.16 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PACS Group has a net margin of 4.49% compared to Viridian Therapeutics' net margin of -490.31%. PACS Group's return on equity of 26.47% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
PACS Group	4.49%	26.47%	4.36%

PACS Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.92M	27.21	-$342.60M	-$3.32	N/A
PACS Group	$5.43B	1.33	$191.54M	$1.56	29.37

Summary

Viridian Therapeutics and PACS Group tied by winning 7 of the 14 factors compared between the two stocks.

How does Viridian Therapeutics compare to Hims & Hers Health?

Viridian Therapeutics (NASDAQ:VRDN) and Hims & Hers Health (NYSE:HIMS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Viridian Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than Viridian Therapeutics. Hims & Hers Health is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.92M	27.21	-$342.60M	-$3.32	N/A
Hims & Hers Health	$2.37B	2.96	$128.37M	-$0.09	N/A

Hims & Hers Health has a net margin of -0.56% compared to Viridian Therapeutics' net margin of -490.31%. Hims & Hers Health's return on equity of 6.10% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Hims & Hers Health	-0.56%	6.10%	1.52%

63.5% of Hims & Hers Health shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hims & Hers Health had 15 more articles in the media than Viridian Therapeutics. MarketBeat recorded 25 mentions for Hims & Hers Health and 10 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Hims & Hers Health's score of 0.22 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	5 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	2 Very Negative mention(s)	Neutral

Viridian Therapeutics presently has a consensus price target of $38.79, indicating a potential upside of 107.19%. Hims & Hers Health has a consensus price target of $31.43, indicating a potential upside of 3.77%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viridian Therapeutics is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19

Summary

Hims & Hers Health beats Viridian Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Billiontoone?

Viridian Therapeutics (NASDAQ:VRDN) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

In the previous week, Viridian Therapeutics had 5 more articles in the media than Billiontoone. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for Billiontoone. Viridian Therapeutics' average media sentiment score of 1.22 beat Billiontoone's score of 0.41 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Viridian Therapeutics currently has a consensus price target of $38.79, suggesting a potential upside of 107.19%. Billiontoone has a consensus price target of $126.00, suggesting a potential downside of 8.05%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Billiontoone has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Billiontoone's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Billiontoone	N/A	N/A	N/A

Billiontoone has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.92M	27.21	-$342.60M	-$3.32	N/A
Billiontoone	$305.11M	20.66	$7.45M	$0.55	249.16

Summary

Billiontoone beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

91.0% of Sotera Health shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sotera Health has a net margin of 9.91% compared to Viridian Therapeutics' net margin of -490.31%. Sotera Health's return on equity of 39.73% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Sotera Health has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.19B	4.33	$77.94M	$0.41	44.08
Viridian Therapeutics	$70.92M	27.21	-$342.60M	-$3.32	N/A

Sotera Health has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

In the previous week, Sotera Health and Sotera Health both had 10 articles in the media. Sotera Health's average media sentiment score of 1.35 beat Viridian Therapeutics' score of 1.22 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health currently has a consensus price target of $20.25, suggesting a potential upside of 12.04%. Viridian Therapeutics has a consensus price target of $38.79, suggesting a potential upside of 107.19%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Sotera Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Sotera Health beats Viridian Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to RadNet?

RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

RadNet has a net margin of -0.66% compared to Viridian Therapeutics' net margin of -490.31%. RadNet's return on equity of 2.77% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

RadNet has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, Viridian Therapeutics had 5 more articles in the media than RadNet. MarketBeat recorded 10 mentions for Viridian Therapeutics and 5 mentions for RadNet. Viridian Therapeutics' average media sentiment score of 1.22 beat RadNet's score of 0.42 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

77.9% of RadNet shares are held by institutional investors. 5.1% of RadNet shares are held by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.53	-$18.65M	-$0.18	N/A
Viridian Therapeutics	$70.92M	27.21	-$342.60M	-$3.32	N/A

RadNet currently has a consensus price target of $87.43, indicating a potential upside of 33.41%. Viridian Therapeutics has a consensus price target of $38.79, indicating a potential upside of 107.19%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.80
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

RadNet beats Viridian Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.94B	$3.51B	$6.81B	$12.55B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.67	7.39	282.12	24.83
Price / Sales	27.21	1,209.27	573.08	78.59
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.03	16.98	11.02	6.15
Net Income	-$342.60M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-4.97%	-1.85%	0.47%	1.17%
1 Month Performance	-3.51%	-8.52%	-4.24%	-3.46%
1 Year Performance	7.52%	47.51%	62.63%	19.43%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.661 of 5 stars	$18.72 -1.1%	$38.79 +107.2%	+8.7%	$1.94B	$70.92M	N/A	50	Positive News Upcoming Earnings Analyst Downgrade Gap Up
PACS PACS Group	3.5397 of 5 stars	$46.95 +0.2%	$50.60 +7.8%	+334.3%	$7.42B	$5.43B	30.09	47,455	Positive News Upcoming Earnings Gap Up
HIMS Hims & Hers Health	2.4877 of 5 stars	$30.23 +7.6%	$31.43 +4.0%	-55.6%	$7.00B	$2.37B	N/A	2,442	Upcoming Earnings
BLLN Billiontoone	2.6264 of 5 stars	$127.98 +1.5%	$126.00 -1.5%	N/A	$5.80B	$305.11M	232.69	620
SHC Sotera Health	3.4653 of 5 stars	$17.24 -0.6%	$20.25 +17.5%	+60.2%	$4.92B	$1.19B	42.05	3,000	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PACS, HIMS, BLLN, SHC, and RDNT

How does Viridian Therapeutics compare to PACS Group?

Summary

How does Viridian Therapeutics compare to Hims & Hers Health?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Summary

How does Viridian Therapeutics compare to Sotera Health?

Summary

How does Viridian Therapeutics compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PACS, HIMS, BLLN, SHC, and RDNT

How does Viridian Therapeutics compare to PACS Group?

Do analysts rate VRDN or PACS?

Which has more risk & volatility, VRDN or PACS?

Does the media prefer VRDN or PACS?

Is VRDN or PACS more profitable?

Which has higher earnings & valuation, VRDN or PACS?

Summary

How does Viridian Therapeutics compare to Hims & Hers Health?

Which has more risk & volatility, VRDN or HIMS?

Which has stronger earnings & valuation, VRDN or HIMS?

Is VRDN or HIMS more profitable?

Do insiders and institutionals have more ownership in VRDN or HIMS?

Does the media prefer VRDN or HIMS?

Do analysts rate VRDN or HIMS?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Does the media favor VRDN or BLLN?

Do analysts rate VRDN or BLLN?

Is VRDN or BLLN more profitable?

Which has stronger valuation and earnings, VRDN or BLLN?

Summary

How does Viridian Therapeutics compare to Sotera Health?

Do institutionals and insiders hold more shares of SHC or VRDN?

Is SHC or VRDN more profitable?

Which has stronger valuation and earnings, SHC or VRDN?

Which has more volatility and risk, SHC or VRDN?

Does the media favor SHC or VRDN?

Do analysts recommend SHC or VRDN?

Summary

How does Viridian Therapeutics compare to RadNet?

Is RDNT or VRDN more profitable?

Which has more volatility and risk, RDNT or VRDN?

Does the media refer more to RDNT or VRDN?

Do institutionals and insiders have more ownership in RDNT or VRDN?

Which has stronger earnings and valuation, RDNT or VRDN?

Do analysts recommend RDNT or VRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools